FDA Approves Sanofi's Multiple Myeloma Drug [The Motley Fool]
Sanofi - American Depositary Shares (SNY)
US:NYSE Investor Relations:
sanofi.com/en/investors
Company Research
Source: The Motley Fool
FDA Approves Sanofi's Multiple Myeloma Drug Patients with this rare blood cancer have another treatment option available to them. The U.S. Food and Drug Administration (FDA) announced that it has approved Sanofi 's ( NASDAQ:SNY ) new drug for patients with reoccurring multiple myeloma. Sarclisa (also known as isatuximab) is a treatment that promotes tumor cell death by targeting a specific protein type found on the surface of white blood cells. The agency approved Sarclisa to be used as a drug combo alongside Bristol-Myers Squibb 's Pomalyst (also known as pomalidomide) and a steroid medication known as dexamethasone. Adult patients who have had at least two previous treatments for multiple myeloma but have had the condition return are eligible for this treatment. "While there is no cure for multiple myeloma, Sarclisa is now another CD38-directed treatment option added to the list of FDA-approved treatments of patients with multiple myeloma who have progressive disease after previous
Show less
Read more
Impact Snapshot
Event Time:
SNY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SNY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SNY alerts
High impacting Sanofi - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
SNY
News
- 1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall Street [Yahoo! Finance]Yahoo! Finance
- These CEO's reveal their top festive reads for the year [Fortune]Fortune
- Olympian Jordan Chiles is setting her sights on a new goal: raising awareness of type 1 diabetes [Fortune]Fortune
- Sanofi's 21-Valent Pneumococcal Vaccine Enters Phase III [Yahoo! Finance]Yahoo! Finance
- SK bioscience and Sanofi expand agreement for pneumococcal conjugate vaccines [Yahoo! Finance]Yahoo! Finance
SNY
Sec Filings
- 12/23/24 - Form 6-K
- 12/20/24 - Form 6-K
- 12/13/24 - Form 6-K
- SNY's page on the SEC website